0001104659-23-082729.txt : 20230720
0001104659-23-082729.hdr.sgml : 20230720
20230720161752
ACCESSION NUMBER: 0001104659-23-082729
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230718
FILED AS OF DATE: 20230720
DATE AS OF CHANGE: 20230720
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Parsey Merdad
CENTRAL INDEX KEY: 0001792150
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41742
FILM NUMBER: 231099917
MAIL ADDRESS:
STREET 1: 333 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sagimet Biosciences Inc.
CENTRAL INDEX KEY: 0001400118
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205991472
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 155 BOVET RD., SUITE 303
CITY: SAN MATEO
STATE: CA
ZIP: 94402
BUSINESS PHONE: (650) 561-8600
MAIL ADDRESS:
STREET 1: 155 BOVET RD., SUITE 303
CITY: SAN MATEO
STATE: CA
ZIP: 94402
FORMER COMPANY:
FORMER CONFORMED NAME: 3-V Biosciences, Inc.
DATE OF NAME CHANGE: 20070521
4
1
tm2321276-18_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-07-18
0
0001400118
Sagimet Biosciences Inc.
SGMT
0001792150
Parsey Merdad
SAGIMET BIOSCIENCES INC.
155 BOVET RD., SUITE 303
SAN MATEO
CA
94402
1
0
0
0
0
Common Stock
2023-07-18
4
D
0
8677
D
0
D
Series A Common Stock
2023-07-18
4
A
0
8677
A
8677
D
Series A Common Stock
2023-07-18
4
C
0
4117
A
12794
D
Series E Preferred Stock
2023-07-18
4
C
0
327309
0
D
Series A Common Stock
4117
0
D
Stock Option (Right to Buy)
11.13
2023-07-18
4
D
0
2086
0
D
2024-03-12
Common Stock
2086
0
D
Stock Option (Right to Buy)
11.13
2023-07-18
4
A
0
2086
0
A
2024-03-12
Series A Common Stock
2086
2086
D
Stock Option (Right to Buy)
23.05
2023-07-18
4
D
0
3349
0
D
2024-12-16
Common Stock
3349
0
D
Stock Option (Right to Buy)
23.05
2023-07-18
4
A
0
3349
0
A
2024-12-16
Series A Common Stock
3349
3349
D
Stock Option (Right to Buy)
23.05
2023-07-18
4
D
0
144
0
D
2025-02-05
Common Stock
144
0
D
Stock Option (Right to Buy)
23.05
2023-07-18
4
A
0
144
0
A
2025-02-05
Series A Common Stock
144
144
D
Stock Option (Right to Buy)
6.36
2023-07-18
4
D
0
23216
0
D
2029-04-27
Common Stock
23216
0
D
Stock Option (Right to Buy)
6.36
2023-07-18
4
A
0
23216
0
A
2029-04-27
Series A Common Stock
23216
23216
D
Stock Option (Right to Buy)
6.36
2023-07-18
4
D
0
23839
0
D
2031-01-26
Common Stock
23839
0
D
Stock Option (Right to Buy)
6.36
2023-07-18
4
A
0
23839
0
A
2031-01-26
Series A Common Stock
23839
23839
D
Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
Upon closing of the Issuer's initial public offering, each share of Series E Preferred Stock automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Series E Preferred Stock had no expiration date.
The shares underlying this option are fully vested and exercisable as of the date hereof.
/s/ Dennis Hom, Attorney-in-Fact
2023-07-20